Which COVID-19 vaccine is associated with Guillain-Barré Syndrome? What's the newest C difficile therapy? Contagion's weekly infectious disease recap has you covered.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Detection of the virulent neurotropic fungus Cladophialophora bantiana in clinical samples, primarily CNS tissue, increased four-fold in the period from 2023 to 2025.
Pritelivir (Hovilpri) healed all lesions by day 28 in 63% of immunocompromised adults with refractory HSV versus 34% with investigator's choice in the phase 3 PRIOH-1 trial.
CDC is continuing its investigation into 4 multistate Salmonella and E coli outbreaks, led by a 76-case alfalfa sprout cluster across 16 states and a recalled raw milk cheese.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
